- Udyam number
- UDYAM-TS-20-0001246

About Orbicular Pharmaceutical Technologies Private Limited
Data last updated:
Orbicular Pharmaceutical Technologies Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 13 August 2008 and has been in existence for over 18 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24233TG2008PTC060606. Its GSTIN is 36AABCO1181G1ZO (Telangana). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹12 Cr and a paid-up capital of ₹11.18 Cr. It is led by directors including Sivaraman Mohan Mailatur (Managing Director) and Hiren Dasharathbhai Patel.
Its last annual general meeting (AGM) was held on 12 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at P.No 53 Aleap Industrial Estate Gajularamaram Behind Pragathi Nagar Kukatpally, Hyderabad, Telangana, India – 500090.
As per the financials filed for FY 2025, the company reported a revenue of ₹261.54 Cr, a growth of 41% compared to the previous year. For the same year it recorded a net profit of ₹28.36 Cr (net margin 10.8%) and EBITDA of ₹96.66 Cr (EBITDA margin 37%). Revenue has grown at a compounded annual rate (CAGR) of 6% over three years.
The company has about 240 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Orbicular Pharmaceutical Technologies. As per MCA filings, the company has open charges of ₹449.05 Cr and satisfied charges of ₹15.7 Cr on record. Court records list 1 case involving the company, including 1 filed against it. The company has 6 deals on record (4 secondary share transfers, 2 funding rounds), with disclosed funding of ₹151.01 Cr; the latest was in May 2024. Its 3 peer companies in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development) are compared by revenue, 2 larger and 1 smaller; the largest is Syngene Scientific Solutions Limited with revenue of ₹334.5 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 51 overdue payments to 41 micro and small suppliers.
Orbicular Pharmaceutical Technologies Private Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-TS-20-0001246). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website orbicular.co.in.
Company details
CIN history
Orbicular Pharmaceutical Technologies has one previous CIN (Corporate Identification Number): U24233AP2008PTC060606. The current CIN is U24233TG2008PTC060606, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24233TG2008PTC060606 | Current |
| U24233AP2008PTC060606 | Previous |
Recognitions & Rankings of Orbicular Pharmaceutical Technologies
Contact details
Orbicular Pharmaceutical Technologies Private Limited's registered office is in Hyderabad, Telangana. Its website is orbicular.co.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressP.No 53 Aleap Industrial Estate Gajularamaram Behind Pragathi Nagar Kukatpally, Hyderabad, Telangana, India – 500090
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Orbicular Pharmaceutical Technologies operates one associated brand: Orbicular Pharmaceutical Technologies. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of niche generic and specialty pharmaceutical products | orbicular.co.in |
Business activity
The main business activity of Orbicular Pharmaceutical Technologies is professional, scientific and technical. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
Financials of Orbicular Pharmaceutical Technologies Private Limited
FY 2025 filings availableOrbicular Pharmaceutical Technologies Private Limited reported revenue of ₹261.54 Cr (up 41% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 6% over three years, including 41% growth in the latest year. EBITDA fell 18% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹261.54 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹96.66 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹28.36 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 37% | ||||
| Net Profit Margin | 10.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
Board of directors of Orbicular Pharmaceutical Technologies Private Limited
Orbicular Pharmaceutical Technologies has 6 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Hiren Dasharathbhai Patel | Director | 24 Aug 2012 | 14 Years 2 Months | Current |
| Sivaraman Mohan Mailatur | Managing Director | 06 Aug 2010 | 16 Years 3 Months | Current |
| Meena Mohan | Director | 13 Aug 2008 | 18 Years 3 Months | Current |
| Rahul Gawande Sudhakar | Director | 01 Jul 2019 | 7 Years 4 Months | Current |
| Bhaveshkumar Vallabhbhai Patel Also directs: Invitron Advanced Analytics Private Limited | Director | 01 Apr 2022 | 4 Years 7 Months | Current |
| Visalakshi Chandramouli Also directs: Sakar Healthcare Limited, Brinton Pharmaceuticals Limited, Linux Laboratories Private Limited and 4 more | Nominee Director | 31 May 2024 | 2 Years 5 Months | Current |
Peer comparison
Orbicular Pharmaceutical Technologies Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Syngene Scientific Solutions Limited | ₹334.5 Cr (FY 2025) | -6.0% | Bangalore, Karnataka, India | |||
| Adgyl Lifesciences Private Limited | ₹272.09 Cr (FY 2025) | -8.0% | Bengaluru, Karnataka, India | |||
| Orbicular Pharmaceutical Technologies Private Limitedthis company | ₹261.54 Cr (FY 2025) | ₹28.36 Cr | 10.8% | 41.0% | 240 | Hyderabad, Telangana, India |
| Pioneer Hi-Bred Private Limited | ₹207.84 Cr (FY 2025) | 16.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
Auditor
Orbicular Pharmaceutical Technologies Private Limited is audited by MN Reddy & Co for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MN Reddy & Co | FY 2024 | 010025S |
Shareholding
The shareholding of Orbicular Pharmaceutical Technologies Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 24 Nov 2025 | 101205765 | Hdfc Bank Limited | ₹40 Cr | Open | |
| 24 Nov 2025 | 101216682 | Hdfc Bank Limited | ₹60 Cr | Open | |
| 30 Oct 2025 | 101203120 | Others | ₹8 Cr | Open | |
| 28 Jun 2025 | 101128736 | Others | ₹4.5 Cr | Open | |
| 28 Jun 2025 | 101128740 | Others | ₹23 Cr | Open |
To see the full charge records of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
Total charge records: 19 View all charges
Deals & funding
Orbicular Pharmaceutical Technologies Private Limited has 6 deals on record (4 secondary share transfers, 2 funding rounds), with disclosed funding of ₹151.01 Cr; the latest was in May 2024.
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2024 | Funding round | ₹150 Cr | Investors: Tata Capital Healthcare Fund |
| Dec 2023 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: an individual |
| Sep 2022 | Secondary share transfer | Undisclosed | Seller: 4 individuals |
| Nov 2018 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Sep 2016 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 2 individuals |
To see the full deal history of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Orbicular Pharmaceutical Technologies Private Limited has 1 court case on record: 1 filed against it. All case is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 1 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, TELANGANA | Petition | Filed against the company by Teva Pharmaceuticals International and 2 others | Disposed |
To see the full case history of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Orbicular Pharmaceutical Technologies Private Limited was last rated by Crisil on 17 Jun 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 17 Jun 2020 |
To see the full credit ratings and regulatory alerts of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
MSME payment delays
Orbicular Pharmaceutical Technologies Private Limited has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 51 overdue payments to 41 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 41)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Lakshmi Venkateshwara Enterprises | |||
| FCM Travel Solutions (India) Private Limited | |||
| an individual supplier | |||
| Deloitte Touche Tohmatsu India LLP |
To see the full MSME payment records of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Orbicular Pharmaceutical Technologies has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Invitron Advanced Analytics Private Limited | U73100TG2013PTC087372 |
To see the full group structure of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
Employees & EPFO
Orbicular Pharmaceutical Technologies Private Limited has a workforce of 240 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 240 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
GST
Orbicular Pharmaceutical Technologies has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AABCO1181G1ZO | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.
Recent activity
Orbicular Pharmaceutical Technologies Private Limited has 11 board changes on record since 2008: 6 appointments and 5 cessations. The latest: Visalakshi Chandramouli was appointed as Nominee Director on 31 May 2024.
32 earlier events are in the company report.
News
Frequently asked questions
Orbicular Pharmaceutical Technologies is an active private limited company based in Hyderabad, Telangana, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 13 August 2008 (18+ years old) and is registered under CIN U24233TG2008PTC060606.
Orbicular Pharmaceutical Technologies has 6 current directors:
- Sivaraman Mohan Mailatur - Managing Director
- Hiren Dasharathbhai Patel - Director
- Meena Mohan - Director
- Rahul Gawande Sudhakar - Director
- Bhaveshkumar Vallabhbhai Patel - Director
- Visalakshi Chandramouli - Nominee Director
The latest financial statements of Orbicular Pharmaceutical Technologies on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 12 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Orbicular Pharmaceutical Technologies is 36AABCO1181G1ZO, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Orbicular Pharmaceutical Technologies is U24233TG2008PTC060606. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Orbicular Pharmaceutical Technologies has 1 court case on record: 1 filed against it.
Orbicular Pharmaceutical Technologies was incorporated on 13 August 2008, making it 18+ years old. It is registered with the Registrar of Companies, Hyderabad.
Orbicular Pharmaceutical Technologies has 6 deals on record (4 secondary share transfers, 2 funding rounds), with disclosed funding of ₹151.01 Cr; the latest was in May 2024.
The peers of Orbicular Pharmaceutical Technologies by revenue are Syngene Scientific Solutions Limited, Adgyl Lifesciences Private Limited, Pioneer Hi-Bred Private Limited, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).
Visalakshi Chandramouli was appointed as Nominee Director on 31 May 2024. Bhavesh Vallabhbhai Patel ceased to be Additional Director on 29 Sep 2022. Bhaveshkumar Vallabhbhai Patel was appointed as Director on 01 Apr 2022. Orbicular Pharmaceutical Technologies has 11 board changes on record in total.
Yes, Orbicular Pharmaceutical Technologies is registered as an MSME under Udyam registration (number: UDYAM-TS-20-0001246).
Orbicular Pharmaceutical Technologies has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 51 overdue payments to 41 micro and small suppliers. The latest return was filed on 04 Jul 2024.

